Tadalafil has more than one approved use, but the correct indication cannot be determined from the drug name alone. In the current U.S. Cialis and corresponding ED/BPH tadalafil tablet context, tadalafil is indicated for erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, and the combined situation in which ED and BPH occur together.
Pulmonary arterial hypertension belongs to a separate tadalafil product context. Adcirca tablets and Tadliq oral suspension are labeled for PAH, specifically WHO Group 1 pulmonary arterial hypertension, to improve exercise ability. That distinction matters because sharing the active ingredient tadalafil does not mean that every tadalafil product carries every tadalafil indication.
This page maps the approved-use landscape rather than reproducing the disease-specific evidence, dosing instructions or safety details for each condition. Detailed treatment context belongs on Tadalafil for Erectile Dysfunction, Tadalafil for BPH, Tadalafil for ED and BPH and Tadalafil for Pulmonary Hypertension.
The most important distinction is between the active molecule and the label of the specific product. Tadalafil can be used in ED/BPH products and in PAH products, but those labeling frameworks should not be collapsed into one universal list of instructions.
The table below shows the principal current U.S. indication contexts and where each deeper intent belongs.
| Product / Label Context | Labeled Use | High-Level Purpose | Dedicated Page |
|---|---|---|---|
| Cialis / ED-BPH tadalafil tablets | Erectile dysfunction (ED) | Treatment of erectile dysfunction | Tadalafil for Erectile Dysfunction |
| Cialis / ED-BPH tadalafil tablets | Signs and symptoms of benign prostatic hyperplasia (BPH) | Treatment of BPH symptoms | Tadalafil for BPH |
| Cialis / ED-BPH tadalafil tablets | ED and signs and symptoms of BPH | Combined labeled context when both conditions are present | Tadalafil for ED and BPH |
| Adcirca | Pulmonary arterial hypertension (WHO Group 1) | Improves exercise ability in the labeled PAH population | Tadalafil for Pulmonary Hypertension |
| Tadliq | Pulmonary arterial hypertension (WHO Group 1) | Oral-suspension PAH product used to improve exercise ability | Tadalafil for Pulmonary Hypertension |
An indication belongs to an approved product label, not simply to a molecule in the abstract. Cialis contains tadalafil and is labeled for ED, BPH and ED/BPH, while Adcirca also contains tadalafil but is labeled for PAH.
Tadliq adds another example because it contains the same active ingredient in an oral suspension formulated and labeled for PAH. This is why the question 'What is tadalafil used for?' is best answered with both the disease and product context attached.
| Statement | Accurate? |
|---|---|
| Tadalafil is the active ingredient in more than one product | Yes |
| Every tadalafil product automatically has every tadalafil indication | No |
| Cialis and Adcirca contain the same active drug | Yes |
| Cialis and Adcirca have identical labeled uses | No |
| The specific product label matters | Yes |
Erectile dysfunction is one of tadalafil's best-known approved uses. Current Cialis and ED/BPH tadalafil tablet labeling indicates tadalafil for the treatment of ED, a condition in which achieving or maintaining an erection sufficient for sexual activity is impaired.
Tadalafil supports the physiological erectile response by inhibiting PDE5 and preserving cGMP signaling after sexual stimulation activates the nitric-oxide pathway. It does not create sexual desire or replace the need for sexual stimulation in the ED mechanism.
The condition-specific clinical context belongs on Tadalafil for Erectile Dysfunction, while the simplified mechanism is covered on How Tadalafil Works.
| ED Use Question | High-Level Answer |
|---|---|
| Is ED a labeled tadalafil use? | Yes, in the Cialis / ED-BPH tablet context. |
| Primary pharmacologic class | PDE5 inhibitor |
| Does tadalafil create sexual stimulation? | No |
| Is ED-specific dosing covered here? | No; see the dedicated dosage and ED pages. |
Current Cialis and generic ED/BPH tablet labeling includes both as-needed and once-daily approaches for erectile dysfunction. This is an important use distinction because the same ED indication can appear within two different treatment patterns.
The existence of both approaches does not make them interchangeable for every patient, and a uses page should not be used to select a regimen. See As-Needed Tadalafil, Daily Tadalafil and Daily vs As-Needed Tadalafil for the regimen-specific framework.
| ED Treatment Context | Labeled at a High Level? |
|---|---|
| As-needed tadalafil | Yes |
| Once-daily tadalafil | Yes |
| Same dosing framework? | No |
| Personal regimen determined by this uses page? | No |
Tadalafil is also indicated in the Cialis/ED-BPH tablet context for the treatment of the signs and symptoms of benign prostatic hyperplasia. BPH is a noncancerous enlargement of the prostate associated with lower urinary tract symptoms such as urinary frequency, urgency, weak stream or difficulty starting urination.
PDE5-related effects on cGMP occur in smooth muscle of the prostate, bladder and their vascular supply, but current labeling states that the mechanism by which tadalafil reduces BPH symptoms has not been established. The approved use should therefore not be reduced to an oversimplified claim that tadalafil merely 'relaxes the prostate.'
The disease-specific evidence belongs on Tadalafil for BPH.
| BPH Question | Answer |
|---|---|
| Is BPH a labeled tadalafil indication? | Yes, in the Cialis / ED-BPH tablet context. |
| What is treated? | The signs and symptoms of BPH. |
| Is the complete therapeutic mechanism established? | No. |
| Is BPH the same condition as ED? | No. |
Current Cialis and corresponding tadalafil tablet labeling includes a specific limitation when tadalafil is used with finasteride to initiate BPH treatment. In that situation, labeling recommends the combination for up to 26 weeks because the incremental benefit of tadalafil decreases over the studied period and benefit beyond 26 weeks is unknown.
This is a product-label limitation rather than a general definition of tadalafil's BPH indication. Detailed BPH treatment decisions and medication combinations require the condition-specific prescribing context rather than interpretation from an indication list alone.
| Finasteride / Tadalafil Point | Label Context |
|---|---|
| Purpose | Initiating BPH treatment with tadalafil plus finasteride |
| Label-recommended period | Up to 26 weeks |
| Reason for limitation | Incremental tadalafil benefit decreases during the studied period; benefit beyond 26 weeks is unknown |
| Does this redefine the general BPH indication? | No |
Current labeling does not merely list ED and BPH independently. It also specifically indicates tadalafil for men who have erectile dysfunction together with signs and symptoms of BPH.
This combined ED/BPH indication is clinically useful because both problems can coexist, but it should not be treated as a third unrelated disease. It is a defined product-label context in which the same tadalafil regimen is used for the combined presentation.
That combined context is covered on Tadalafil for ED and BPH.
| Use | Label Structure |
|---|---|
| ED alone | Separate indication |
| BPH symptoms alone | Separate indication |
| ED with BPH symptoms | Explicit combined indication |
| A new disease called ED/BPH | No; it is a combined treatment context |
A combined indication prevents the use map from being reduced to 'tadalafil treats ED and separately treats BPH.' Current labeling expressly recognizes the population in which both conditions are present and provides a specific once-daily treatment context for that situation.
The combined label also reinforces why indication and regimen need to stay connected. As-needed ED use should not be assumed to represent the same product framework used for combined ED/BPH treatment.
Regimen details remain on Tadalafil Dosage rather than this indication hub.
| Question | Answer |
|---|---|
| Does ED/BPH appear explicitly in labeling? | Yes |
| Is it simply another name for as-needed ED use? | No |
| Does the uses page determine an individual's regimen? | No |
Tadalafil is also used for pulmonary arterial hypertension, but this belongs to a different product-label branch from Cialis-style ED/BPH treatment. Current Adcirca labeling indicates tadalafil for PAH, WHO Group 1, to improve exercise ability.
PAH involves elevated pressure in the pulmonary arterial circulation and places increased workload on the right side of the heart. PDE5 inhibition increases available cGMP signaling in pulmonary vascular smooth muscle and promotes pulmonary vasodilation, but the full disease-management context extends beyond this mechanism summary.
See Tadalafil for Pulmonary Hypertension for the indication-specific page.
| PAH Label Feature | Adcirca Context |
|---|---|
| Condition | Pulmonary arterial hypertension |
| WHO classification in label | WHO Group 1 |
| Labeled treatment objective | Improve exercise ability |
| Same labeled use as Cialis? | No |
Adcirca contains tadalafil in 20 mg tablets and is labeled specifically for pulmonary arterial hypertension rather than the ED/BPH indications associated with Cialis. Its prescribing framework therefore follows the PAH product label even though the underlying active ingredient is the same molecule.
This provides a clear example of why a brand name and indication cannot be separated. More product-specific information is available on Adcirca.
| Feature | Adcirca |
|---|---|
| Active ingredient | Tadalafil |
| Dosage form | Oral tablet |
| Tablet strength | 20 mg |
| Labeled indication | PAH (WHO Group 1) |
| Labeled objective | Improve exercise ability |
Tadliq is a tadalafil oral suspension containing 20 mg per 5 mL and is also indicated for PAH, WHO Group 1, to improve exercise ability. It demonstrates that tadalafil's product-specific indication differences involve not only brand naming but also dosage form.
Tadliq should not be described simply as a liquid version of ED tadalafil because its current U.S. labeling is built around the PAH indication. Product details belong on Tadliq and formulation questions on Tadalafil Oral Suspension.
| Feature | Tadliq |
|---|---|
| Active ingredient | Tadalafil |
| Dosage form | Oral suspension |
| Strength | 20 mg/5 mL |
| Labeled indication | PAH (WHO Group 1) |
| Labeled objective | Improve exercise ability |
Cialis, Adcirca and Tadliq all rely on tadalafil as the active ingredient, but regulatory labeling defines different therapeutic contexts around the products. The molecule's PDE5-inhibiting pharmacology is shared, while the disease, dosage form, dosing framework and clinical evidence supporting each label can differ.
This is why the active ingredient should be treated as one entity and the approved product labels as distinct layers around that entity. A molecule-level overview is available on What Is Tadalafil?.
| Shared Across Product Contexts | Can Differ by Product |
|---|---|
| Active molecule: tadalafil | Approved indication |
| PDE5 inhibitor pharmacology | Dosage form |
| Core tadalafil identity | Strength presentation |
| Core molecular mechanism | Regimen and prescribing instructions |
| Core drug safety concepts | Condition-specific evidence and labeling |
Current U.S. Cialis labeling lists three indication lines: erectile dysfunction, the signs and symptoms of BPH, and ED together with the signs and symptoms of BPH. PAH is not part of the current Cialis indication list.
The fact that tadalafil itself also appears in PAH products should therefore not be rewritten as 'Cialis treats PAH.' Brand-specific statements should follow the indication actually attached to that brand.
For brand-specific information see Cialis and Tadalafil and Cialis.
| Cialis Use | Current U.S. Label? |
|---|---|
| Erectile dysfunction | Yes |
| Signs and symptoms of BPH | Yes |
| ED with signs and symptoms of BPH | Yes |
| Pulmonary arterial hypertension | No; PAH belongs to separate tadalafil product contexts |
Many current generic tadalafil tablet labels corresponding to the ED/BPH treatment context list ED, BPH and ED/BPH as indications. However, the word 'generic' identifies regulatory product status rather than one universal therapeutic indication for every possible tadalafil product.
A generic tadalafil product should therefore be interpreted according to the label and reference-product context under which it was approved. The active molecule may be the same while indication, dosage form and prescribing framework differ across products.
For the broader generic-drug context see Generic Tadalafil.
| Generic Tadalafil Question | Answer |
|---|---|
| Does generic mean the active ingredient is tadalafil? | Yes |
| Does the word generic by itself specify the indication? | No |
| Should the approved product label be checked? | Yes |
| Can product context matter even with the same molecule? | Yes |
Tadalafil's common molecular action is PDE5 inhibition, but an approved indication requires clinical evidence in a defined disease and product context. Knowing that PDE5 is present in a tissue does not automatically establish that tadalafil is approved or effective for every condition involving that tissue.
The mechanism therefore explains biological plausibility, while labeling identifies the uses supported within a regulatory framework. The plain-language mechanism is covered on How Tadalafil Works.
| Concept | Question It Answers |
|---|---|
| Mechanism | What does tadalafil do biologically? |
| Clinical evidence | Does treatment improve a defined outcome in a studied population? |
| Approved indication | For what use has a specific product been labeled? |
| Target presence in a tissue | Does not by itself establish an approved use |
Knowing that tadalafil is used for ED, BPH or PAH is only the first part of the prescribing context. Different indications and products use different regimen structures, so a dose cannot be inferred simply from the word tadalafil.
This is especially clear when comparing as-needed ED use, once-daily ED/BPH use and PAH products. Rather than duplicating those instructions here, the dosing framework is handled on Tadalafil Dosage.
| Use Context | Does the Same Regimen Automatically Apply? |
|---|---|
| ED as needed | No |
| ED once daily | No |
| BPH | No |
| ED/BPH | No |
| PAH | No |
Tadalafil is widely available as an oral tablet, but the existence of Tadliq shows why the dosage form can also signal a different product framework. A tadalafil oral suspension labeled for PAH should not be assumed to inherit the ED/BPH uses of an ED/BPH tablet label.
Formulation, indication and product name therefore need to be read together. Detailed format information belongs on Tadalafil Formulations, Tadalafil Tablets and Tadalafil Oral Suspension.
| Example | Why Product Context Matters |
|---|---|
| Cialis tablet | ED/BPH labeling |
| Adcirca tablet | PAH labeling |
| Tadliq oral suspension | PAH labeling |
| Same active ingredient | Does not erase those labeling differences |
Medicines can sometimes be prescribed in clinical practice outside the exact wording of an approved label, but that is a different question from identifying tadalafil's established product indications. The core use map on this page is intentionally limited to the labeled ED, BPH, ED/BPH and PAH contexts supported by current U.S. tadalafil product information.
A possible biological rationale or a published study in another condition should not automatically be described as an approved tadalafil use. Keeping labeled indications separate from investigational or off-label contexts prevents the use list from becoming misleading.
| Evidence / Use Statement | Does It Automatically Equal an Approved Indication? |
|---|---|
| Current product labeling lists the condition | Yes, for that product |
| PDE5 is present in relevant tissue | No |
| A mechanistic hypothesis exists | No |
| A study has investigated tadalafil | Not necessarily |
| A clinician uses a drug off label | No; off-label use is not a labeled indication |
The Adcirca and Tadliq labels specify pulmonary arterial hypertension, WHO Group 1. Pulmonary hypertension is a broader clinical category with multiple causes and classifications, so the PAH indication should not be generalized to every condition involving elevated pulmonary pressure.
This distinction is important because product labeling and treatment evidence are tied to the defined PAH population. Disease-specific interpretation belongs on Tadalafil for Pulmonary Hypertension.
| Term | Use Context |
|---|---|
| Pulmonary arterial hypertension | WHO Group 1; included in Adcirca and Tadliq labeling |
| Pulmonary hypertension generally | Broader category; should not automatically be treated as the labeled tadalafil indication |
| Adcirca / Tadliq objective | Improve exercise ability in the labeled PAH context |
An approved indication establishes that a product has a recognized therapeutic use, but it does not remove contraindications, drug interactions or patient-specific safety considerations. Tadalafil products have important restrictions involving organic nitrates, guanylate-cyclase stimulators and other clinical factors.
The use list should therefore answer what tadalafil is approved to treat rather than who personally should take it. Safety screening belongs on Tadalafil Contraindications, Tadalafil Warnings and Tadalafil Drug Interactions.
| Question | Answered by Approved Indication Alone? |
|---|---|
| Is tadalafil labeled for this condition in this product context? | Yes |
| Is tadalafil safe for this specific person? | No |
| Can it be combined with all other medicines? | No |
| Which regimen is appropriate? | Not from the indication alone |
The most common error is treating tadalafil as though it has one universal label across every brand, dosage form and generic product. Another is assuming that because tadalafil is widely known for ED, all tadalafil products are ED medicines, or conversely that PAH labeling for Adcirca means Cialis itself is labeled for PAH.
A more accurate approach identifies the active ingredient first and then checks the product-specific indication. ED, BPH, ED/BPH and PAH are all part of the broader tadalafil use landscape, but they belong to different labeled product contexts.
| Misunderstanding | More Accurate Interpretation |
|---|---|
| "Tadalafil is only an ED drug" | Tadalafil also has BPH, ED/BPH and PAH product contexts. |
| "Every tadalafil product treats ED" | No; Adcirca and Tadliq are PAH products. |
| "Cialis is approved for PAH because tadalafil is used for PAH" | No; current Cialis labeling lists ED, BPH and ED/BPH. |
| "Adcirca and Cialis are completely different active drugs" | No; both contain tadalafil. |
| "Any pulmonary hypertension is a tadalafil indication" | No; the PAH labels specify WHO Group 1. |
| "An indication tells me which dose to take" | No; dosing is a separate product- and patient-specific question. |
Tadalafil's approved uses are easier to understand when the indication hub stays separate from the disease-specific pages. This page identifies which conditions belong to which product branches; the child pages can then explain evidence, mechanism, treatment context and limitations without forcing all indications into one oversized article.
For product identity rather than disease use, see the separate Cialis, Adcirca and Tadliq pages.
| Question | Dedicated Page |
|---|---|
| How is tadalafil used for erectile dysfunction? | Tadalafil for Erectile Dysfunction |
| How is tadalafil used for BPH? | Tadalafil for BPH |
| What if ED and BPH occur together? | Tadalafil for ED and BPH |
| How is tadalafil used in PAH? | Tadalafil for Pulmonary Hypertension |
| What is Cialis? | Cialis |
| What is Adcirca? | Adcirca |
| What is Tadliq? | Tadliq |
| What other tadalafil brand names exist? | Tadalafil Brand Names |
| How do tadalafil regimens differ? | Tadalafil Dosage |
| What is tadalafil as a drug entity? | What Is Tadalafil? |
In current U.S. product labeling, tadalafil is used in different product contexts for erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia, combined ED with BPH, and pulmonary arterial hypertension. The applicable use depends on the specific tadalafil product.
Yes. Cialis and tadalafil tablets in the ED/BPH product context are indicated for the treatment of erectile dysfunction.
Yes. Current Cialis and corresponding ED/BPH tadalafil tablet labeling includes treatment of the signs and symptoms of benign prostatic hyperplasia.
Current U.S. Cialis and ED/BPH tadalafil tablet labeling includes a specific combined indication for erectile dysfunction together with the signs and symptoms of BPH. This is a defined once-daily product context rather than a separate disease.
Yes, in specific PAH products. Adcirca tablets and Tadliq oral suspension are labeled for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.
Current U.S. Cialis labeling lists ED, BPH and combined ED/BPH, not PAH. Pulmonary arterial hypertension belongs to separate tadalafil product contexts such as Adcirca and Tadliq.
Adcirca contains tadalafil as its active ingredient. It is a PAH-specific tadalafil brand with its own product labeling rather than an ED/BPH Cialis product.
Tadliq is a tadalafil oral suspension labeled for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.
No. Approved indications attach to specific products and labels. Products can contain the same tadalafil molecule while differing in approved indication, dosage form and dosing framework.
The word generic does not by itself determine the indication. Many generic tadalafil tablet labels in the ED/BPH product context include ED, BPH and ED/BPH, but the approved label of the specific product should be used to identify its indications.
Tadalafil is indicated to treat erectile dysfunction, but an approved treatment is not the same as a permanent cure. Its PDE5-inhibiting effect supports the erectile response when the relevant physiological signaling is active.
Tadalafil is labeled to treat the signs and symptoms of BPH; this does not mean it removes the underlying prostate enlargement or permanently cures BPH. The complete mechanism by which tadalafil improves BPH symptoms has not been established.
Both uses involve PDE5 and cGMP-dependent smooth-muscle physiology, but in different tissues. In ED the relevant effect involves erectile tissue and blood flow, while in PAH PDE5 inhibition promotes relaxation of pulmonary vascular smooth muscle.
No. Current Adcirca and Tadliq labeling specifies pulmonary arterial hypertension, WHO Group 1. Pulmonary hypertension is a broader category and should not be treated as a single tadalafil indication.
No. Different indications and products use different treatment frameworks, including as-needed and once-daily contexts. Dosing should be interpreted from the applicable product labeling and clinical situation.
Current Cialis and ED/BPH tadalafil tablet labeling includes a limitation for use with finasteride when initiating BPH treatment: that combination is recommended for up to 26 weeks because the incremental tadalafil benefit decreases during the studied period and benefit beyond 26 weeks is unknown.
No. An off-label use is different from an indication specifically listed in an approved product label. This page focuses on the labeled ED, BPH, ED/BPH and PAH product contexts.